Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 2 2000
Play
Audio Below:
The
Scottish trial came along and that was very compelling – half
of the patients getting CMF and half of them getting ovarian ablation.
But they used IV CMF, and there is a randomized trial from the EORTC,
which many American physicians are aware of because of the European
literature, but it did show very clearly that classic CMF is superior
to IV CMF. In fact in the superior survival for patients with metastatic
breast cancer, we can be pretty sure that’s true in the case
of early breast cancer as well. So we discounted the Scottish trial
as probably being inadequate chemotherapy and not really a good
comparison. And then, of course, last year we had four trials at
one time. Now looking at medical ovarian ablation for the first
time, using Zoladex in each of those trials and first of all, would
have to come to the conclusion that indirect comparisons of the
results in those four trials provide pretty compelling evidence
that medical ovarian ablation is just as good as surgery or radiation.
Combined
endocrine therapy for breast cancer - New life for an old idea? Davidson, N. E. (Reprint available from: Davidson NE Johns Hopkins
Oncol Ctr 1650 Orleans St,Rm 409 Baltimore, MD 21231 USA). Journal
of the National Cancer Institute 92(11):859-860, 2000 Jun 7. No
abstract
